Pfizer Inc. (PFE) Net Profit Margin: 11.83%
Is Pfizer Inc.’s net profit margin high or low?
Pfizer Inc.'s net profit margin of 11.83% is 35% below its 5-year average of 18.18%, near the low end of its 5-year range (3.58%–31.26%).
As of Thursday, June 11, 2026. 5.44% below its 12-month average of 12.51%.
PFE Net Profit Margin Chart
PFE Average Net Profit Margin Chart
PFE Current vs Average Net Profit Margin Chart
PFE Net Profit Margin Metrics
NET PROFIT MARGIN
11.83%
NET PROFIT MARGIN AVG TTM
12.51%
NET PROFIT MARGIN AVG 3Y
14.97%
NET PROFIT MARGIN AVG 5Y
18.18%
NET PROFIT MARGIN AVG 10Y
21.63%
NET PROFIT MARGIN AVG 15Y
20.20%
NET PROFIT MARGIN AVG 20Y
19.66%
CURRENT VS TTM AVG
-5.44%
CURRENT VS 3Y AVG
-20.95%
CURRENT VS 5Y AVG
-34.94%
CURRENT VS 10Y AVG
-45.30%
CURRENT VS 15Y AVG
-41.45%
CURRENT VS 20Y AVG
-39.84%
PFE Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $149.61B | 11.83% | 12.51% | 14.97% | 18.18% |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 28.15% | 28.09% | 25.67% | 26.14% |
| Abbott Laboratories (ABT) | $155.75B | 13.91% | 23.34% | 19.20% | 17.71% |
| Gilead Sciences, Inc. (GILD) | $156.35B | 30.99% | 15.29% | 17.07% | 15.27% |
| CVS Health Corporation (CVS) | $126.70B | 0.72% | 0.84% | 1.34% | 1.79% |
| Danaher Corporation (DHR) | $126.39B | 14.89% | 15.52% | 19.51% | 19.37% |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 15.18% | 14.95% | 14.84% | 16.47% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 15.01% | -1.95% | 6.91% | 3.59% |
| Amgen Inc. (AMGN) | $188.37B | 20.95% | 16.61% | 20.49% | 22.20% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 35.40% | 13.94% | 25.44% | 29.40% |
Margin Comparison
Operating Margin
23.4%
Net Profit Margin
11.8%
Pfizer Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Net Profit Margin FAQ
- What is the net profit margin for Pfizer Inc. (PFE)?
- The net profit margin for PFE stock is 11.83%.
- Is Pfizer Inc.'s net profit margin high or low?
- Pfizer Inc.'s net profit margin of 11.83% is 35% below its 5-year average of 18.18%, near the low end of its 5-year range (3.58%–31.26%).
- What is the TTM average net profit margin for Pfizer Inc. (PFE)?
- The TTM average net profit margin for PFE stock is 12.51%.
- What is the 3Y average net profit margin for Pfizer Inc. (PFE)?
- The 3Y average net profit margin for PFE stock is 14.97%.
- What is the 5Y average net profit margin for Pfizer Inc. (PFE)?
- The 5Y average net profit margin for PFE stock is 18.18%.
- What is the 10Y average net profit margin for Pfizer Inc. (PFE)?
- The 10Y average net profit margin for PFE stock is 21.63%.
- What is the 15Y average net profit margin for Pfizer Inc. (PFE)?
- The 15Y average net profit margin for PFE stock is 20.20%.
- What is the 20Y average net profit margin for Pfizer Inc. (PFE)?
- The 20Y average net profit margin for PFE stock is 19.66%.
Pfizer Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 12.42% |
| 2024-12-31 | 12.60% |
| 2023-12-31 | 3.58% |
| 2022-12-31 | 31.26% |
| 2021-12-31 | 27.25% |
| 2020-12-31 | 21.99% |
| 2019-12-31 | 39.52% |
| 2018-12-31 | 20.79% |
| 2017-12-31 | 40.55% |
| 2016-12-31 | 13.66% |
| 2015-12-31 | 14.26% |
| 2014-12-31 | 18.30% |
| 2013-12-31 | 22.58% |
| 2012-12-31 | 17.91% |
| 2011-12-31 | 14.26% |
| 2010-12-31 | 12.33% |
| 2009-12-31 | 17.27% |
| 2008-12-31 | 16.61% |
| 2007-12-31 | 16.95% |
| 2006-12-31 | 22.79% |
| 2005-12-31 | 16.05% |
| 2004-12-31 | 21.58% |
| 2003-12-31 | 8.65% |
| 2002-12-31 | 28.19% |
| 2001-12-31 | 24.14% |
| 2000-12-31 | 12.60% |
| 1999-12-31 | 19.62% |
| 1998-12-31 | 24.74% |
| 1997-12-31 | 17.70% |
| 1996-12-31 | 17.06% |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla